Pharmacogenomics (PGx) is the study of genetic variation as it relates to drug response. PGx studies, consisting of testing individuals for multiple variants in drug metabolism enzyme (DME) and transporter genes, are increasing in significance as personalized medicine becomes a reality in standard practice. Technologies that are fast, accurate, cost-effective, and have broad marker coverage are required to support the growing number of PGx studies being conducted. Advances in personalized medicine have led to an increase in pharmacogenomics studies that involve testing individuals for drug metabolism enzyme and transporter gene polymorphisms implicated in drug response. As a consequence, there is a growing demand for affordable, easy to use technologies with fast sample-to-results workflows that can accommodate testing customizable sets of target gene variants and a changeable number of samples. Additionally, data analysis tools are needed to facilitate translation of an individualââ¬â¢s genetic information to
their diploid content of gene-level star allele haplotypes, which can be correlated with drug metabolism enzyme phenotypes.Pharmacogenomics studies typically use genotyping and copy
number analysis to understand the impact of genetic variation on drug, metabolism, drug efficacy, and adverse drug effects. As pharmacogenomics becomes more widespread, there is a need for simple, streamlined workflow solutions to accomplish studies on varying numbers of samples and target genes. (Toinette Hartshorne, Ferrier Le, Jordan Lang, Harrison Leong, Kathleen Hayashibara, Dominique Dewolf and Elliot Shelton, A High-throughput Real-time PCR Approach to Pharmacogenomics Studies)
Last date updated on May, 2025